{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06424834",
            "orgStudyIdInfo": {
                "id": "IRB-75085"
            },
            "secondaryIdInfos": [
                {
                    "id": "24POST1189688",
                    "type": "OTHER_GRANT",
                    "domain": "American Heart Association"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries",
            "officialTitle": "A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study",
            "acronym": "MVP-ANOCA",
            "therapeuticArea": [
                "Cardiovascular",
                "Other"
            ],
            "study": "efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-12",
            "studyFirstSubmitQcDate": "2024-05-16",
            "studyFirstPostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Christopher Chi-Yuen Wong",
                "investigatorTitle": "Postdoc",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "American Heart Association",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 50 days. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study."
        },
        "conditionsModule": {
            "conditions": [
                "Angina Pectoris",
                "Microvascular Angina",
                "Vasospastic Angina",
                "Myocardial Bridge of Coronary Artery"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Targeted medical therapy",
                    "type": "EXPERIMENTAL",
                    "description": "1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose\n2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose\n3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose\n4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Amlodipine 2.5mg initial dose, 10mg max dose; PLUS Nebivolol 5mg initial dose, 20mg max dose\n\nParticipants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for 4 weeks to the conclusion of the study.",
                    "interventionNames": [
                        "Drug: Amlodipine",
                        "Drug: Nebivolol"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "1. Epicardial or microvascular coronary spasm: Placebo\n2. Coronary microvascular dysfunction: Placebo\n3. Myocardial Bridge: Placebo\n4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Placebo\n\nParticipants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for 4 weeks to the conclusion of the study.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Amlodipine",
                    "description": "Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.",
                    "armGroupLabels": [
                        "Targeted medical therapy"
                    ],
                    "otherNames": [
                        "Norvasc",
                        "Katerzia",
                        "Norliqva"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nebivolol",
                    "description": "Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.",
                    "armGroupLabels": [
                        "Targeted medical therapy"
                    ],
                    "otherNames": [
                        "Bystolic"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo taken once orally daily.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Seattle Angina Questionnaire summary score",
                    "description": "Change in Seattle Angina Questionnaire summary score at 7 weeks compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "EuroQol 5 dimension - 5L index score",
                    "description": "Change in EuroQol 5 dimension score - 5L index score at 7 weeks compared to baseline. The index ranges from -0.573 to 1.000, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "EuroQol 5 dimension - 5L visual analogue score",
                    "description": "Change in EuroQol 5 dimension score - 5L visual analogue score at 7 weeks compared to baseline. The index ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "PHQ-4 score",
                    "description": "Change in PHQ-4 at 7 weeks compared to baseline. The score ranges from 0 - 12, with a higher score indicating a worse outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Treatment Satisfaction Questionnaire for Medication score",
                    "description": "Change in Treatment Satisfaction Questionnaire for Medication score at 7 weeks compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Seattle Angina Questionnaire summary score stratified by specific chest pain endotypes",
                    "description": "Change in Seattle Angina Questionnaire summary score at 7 weeks stratified by specific chest pain endotypes at 7 weeks compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "EuroQol 5 dimension - 5L index score stratified by specific chest pain endotypes",
                    "description": "EuroQol 5 dimension - 5L index score at 7 weeks stratified by specific chest pain endotypes at 7 weeks compared to baseline. The index ranges from -0.573 to 1.000, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "EuroQol 5 dimensions - 5L visual analogue score stratified by specific chest pain endotypes",
                    "description": "EuroQol 5 dimensions - 5L visual analogue score at 7 weeks stratified by specific chest pain endotypes at 7 weeks compared to baseline. The index ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "PHQ-4 scores stratified by specific chest pain endotypes",
                    "description": "PHQ-4 score at 7 weeks stratified by specific chest pain endotypes at 7 weeks compared to baseline. The score ranges from 0 - 12, with a higher score indicating a worse outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Treatment Satisfaction Questionnaire for Medication score stratified by specific chest pain endotypes",
                    "description": "Treatment Satisfaction Questionnaire for Medication scores at 7 weeks stratified by specific chest pain endotypes at 7 weeks compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Seattle Angina Questionnaire summary score stratified by baseline angina frequency",
                    "description": "Change in Seattle Angina Questionnaire summary score stratified by baseline angina frequency at at 7 weeks compared to baseline. The score ranges from 0 - 100, with a higher score indicating a better outcome.",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Proportion of patients with good response, no angina, and excellent health status",
                    "description": "Difference between targeted medical therapy group and placebo group in proportion of patients with good response (Seattle Angina Questionnaire summary score \u2265 10), no angina (Seattle Angina Questionnaire angina frequency score = 100), and excellent health status (Seattle Angina Questionnaire summary score \u2265 75).",
                    "timeFrame": "7 weeks"
                },
                {
                    "measure": "Safety endpoints",
                    "description": "Incidence of bleeding, coronary dissection, stroke, periprocedural myocardial infarction, non-self-limiting arrhythmias during the index coronary function testing procedure",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Major adverse cardiac events",
                    "description": "Difference between targeted medical therapy group and placebo group in incidence of cardiac death, myocardial infarction, and hospital presentation for unstable angina.",
                    "timeFrame": "7 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd \u2265 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\< 2.0\n* Index of microcirculatory resistance \u2265 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio \u2264 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\< 95 mmHg\n* Baseline heart rate \\< 55 bpm",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Christopher Wong, MBBS, PhD",
                    "role": "CONTACT",
                    "phone": "(650) 725 5909",
                    "email": "ccywong@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jennifer Tremmel, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford Hospital",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christopher Wong, MBBS, PhD",
                            "role": "CONTACT",
                            "phone": "650-725-5909",
                            "email": "ccywong@stanford.edu"
                        },
                        {
                            "name": "Jennifer Tremmel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000787",
                    "term": "Angina Pectoris"
                },
                {
                    "id": "D000017566",
                    "term": "Microvascular Angina"
                },
                {
                    "id": "D000000788",
                    "term": "Angina Pectoris, Variant"
                },
                {
                    "id": "D000054084",
                    "term": "Myocardial Bridging"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017202",
                    "term": "Myocardial Ischemia"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002637",
                    "term": "Chest Pain"
                },
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000000789",
                    "term": "Angina, Unstable"
                },
                {
                    "id": "D000003330",
                    "term": "Coronary Vessel Anomalies"
                },
                {
                    "id": "D000006330",
                    "term": "Heart Defects, Congenital"
                },
                {
                    "id": "D000018376",
                    "term": "Cardiovascular Abnormalities"
                },
                {
                    "id": "D000000013",
                    "term": "Congenital Abnormalities"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4117",
                    "name": "Angina Pectoris",
                    "asFound": "Angina",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19816",
                    "name": "Microvascular Angina",
                    "asFound": "Microvascular Angina",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4118",
                    "name": "Angina Pectoris, Variant",
                    "asFound": "Vasospastic Angina",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27563",
                    "name": "Myocardial Bridging",
                    "asFound": "Myocardial Bridge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6546",
                    "name": "Coronary Artery Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M19506",
                    "name": "Myocardial Ischemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10543",
                    "name": "Ischemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M5882",
                    "name": "Chest Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M4119",
                    "name": "Angina, Unstable",
                    "relevance": "LOW"
                },
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M6552",
                    "name": "Coronary Vessel Anomalies",
                    "relevance": "LOW"
                },
                {
                    "id": "M9418",
                    "name": "Heart Defects, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M20503",
                    "name": "Cardiovascular Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "T4716",
                    "name": "Prinzmetal's Variant Angina",
                    "asFound": "Vasospastic Angina",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017311",
                    "term": "Amlodipine"
                },
                {
                    "id": "D000068577",
                    "term": "Nebivolol"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000002121",
                    "term": "Calcium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000077264",
                    "term": "Calcium-Regulating Hormones and Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000014665",
                    "term": "Vasodilator Agents"
                },
                {
                    "id": "D000058665",
                    "term": "Adrenergic beta-1 Receptor Agonists"
                },
                {
                    "id": "D000000318",
                    "term": "Adrenergic beta-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19600",
                    "name": "Amlodipine",
                    "asFound": "Vitamin D",
                    "relevance": "HIGH"
                },
                {
                    "id": "M276",
                    "name": "Nebivolol",
                    "asFound": "Instructor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5384",
                    "name": "Calcium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3670",
                    "name": "Adrenergic beta-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                }
            ]
        }
    },
    "hasResults": false
}